The Swedish Patent and Registration Office intends to grant Brighter's patent application.
The Swedish Patent and Registration Office intends to grant Brighter's patent application no. 1550571-2, regarding method and device for logging drug injections made by a medical device with injector.
The patent covers a unique method for identifying whether an injection has occurred or not. After being registered in Sweden, the patent will be expanded to additional markets.
– Over the years, Brighter has built an strong IP portfolio, and we are continuously strengthening it even further through continuous development within both current and new upcoming business areas. As part of the company's long-term strategy IP is considered an active asset that strengthens existing business but also enables e.g. licensing, says Truls Sjöstedt, Brighter's CEO and founder.
The final decision will be published in the Swedish Patent Gazette No. 2017/51 with publication date 2017-12-19. The patent’s publication number will be 539 856.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on November 23, 2017.